Novo Nordisk's ZEUS Setback Casts a Long Shadow Over Its Midyear Report
Published on 08/02/2026 at 17:52 | Redaktion boerse-global.de
The Danish pharmaceutical giant heads into its most consequential trading session of the summer with the market's attention fixed on a single question: can the numbers due Wednesday outweigh the damage done by a failed heart-drug trial? Novo Nordisk's shares tumbled 8.48 percent on Friday, closing at EUR 40.90, after the company disclosed that its experimental cardiovascular treatment Ziltivekimab had missed its primary endpoint in the Phase 3 ZEUS study.
That closing price leaves the stock hovering barely 1.35 percent above its 200-day moving average of EUR 40.35 — a technical support level that chart watchers now view as the dividing line between a contained pullback and a slide toward the March low of EUR 30.25. The 14-day relative strength index sits at 41.8, suggesting the sell-off has pushed the shares toward oversold territory without triggering the kind of capitulation that often marks a bottom.
What Went Wrong in the ZEUS Trial
The setback stems from data released July 31, when Novo Nordisk revealed that Ziltivekimab — an IL-6 inhibitor acquired through the $725 million takeover of Corvidia Therapeutics in 2020 — successfully suppressed inflammatory markers in the blood but failed to produce a statistically significant reduction in heart attacks, strokes, and cardiovascular deaths compared with placebo. The company has flagged a non-cash impairment charge for the third quarter, though it has left its full-year operating profit guidance untouched.
The market's reaction, however, has been anything but uniform. UBS analyst Matthew Weston argues the sell-off may actually understate the damage, noting that his firm had previously modeled roughly $3 billion in peak sales for the drug — about 60 percent of consensus expectations — and that Ziltivekimab accounted for just 1.7 percent of Novo Nordisk's net present value. Weston expects the market response to run two to three times larger than the pure valuation impact, reasoning that the failure intensifies scrutiny of the broader pipeline.
Mizuho's Jared Holz echoes that caution, describing the early data as disappointing and warning that the result could weigh on sentiment across Novo's programs beyond its blockbuster obesity franchise. Others see the decline as overdone: of the 26 analysts covering the stock, 18 currently rate it a "hold," and the average price target implies upside of roughly 4.45 percent from pre-sell-off levels.
When clinical setbacks hit, companies scrutinise every operational risk — and workplace safety documentation is no exception. Many UK employers discover they have gaps in their risk assessments only when an incident occurs. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly before they become problems. Download the free Risk Assessment Toolkit
A Head-to-Head With Eli Lilly
Wednesday's earnings release lands with unusual timing. Novo Nordisk reports first-half 2026 results on August 5, the same day archrival Eli Lilly delivers its second-quarter numbers — setting up an effective side-by-side comparison of the two GLP-1 heavyweights at a moment when investor patience is thinning.
The focal point will be the oral version of semaglutide, Wegovy's tablet formulation, which received EU approval earlier this year. Management commentary on production capacity and supply constraints for the second half will likely carry more weight than the headline figures, given how sensitive the stock has become to execution signals. The shares have already endured a bruising stretch: they stand 25.45 percent below the January high of EUR 54.86, and the 30-day volatility reading of 35.8 percent underscores just how jittery positioning has become.
Legal Clouds and Pipeline Questions
Beyond the trial failure, investors must also contend with a lingering legal overhang. A US class action accuses Novo Nordisk of misleading shareholders about the CagriSema study, and a federal judge recently allowed parts of the case to proceed, ruling that plaintiffs had plausibly argued certain statements about tolerability and trial design were misleading. The company denies the allegations and says it will defend itself vigorously; no finding of securities fraud has been made.
Meanwhile, the pipeline story continues on parallel tracks. The cardiovascular studies HERMES and ARTEMIS — examining Ziltivekimab in heart-failure patients and post-heart-attack populations, respectively — are still running, with results expected in the first half of 2027. A capital markets day on September 21 is slated to lay out Novo Nordisk's transition from injection-based therapies to a broader cardiometabolic portfolio.
The Technical Crossroads
For now, the immediate question is whether the 200-day line holds. The stock closed Friday essentially on its 50-day average of EUR 40.90, a level that offers little in the way of additional support if sellers return. The first-half report will show in detail how pricing pressure in the weight-loss market, the Wegovy tablet rollout, and competitive dynamics with Lilly are reshaping the business — and whether the recent guidance raise from May, which followed stronger-than-expected first-quarter Wegovy sales, can survive contact with reality.
Just as investors demand transparency from pharma companies, regulators expect employers to document their safety procedures thoroughly. If your business handles hazardous substances, you have a legal duty to assess those risks under COSHH regulations. A free toolkit with 43 customisable templates and toolbox talks makes compliance straightforward — no hours of paperwork required. Get the free COSHH Toolkit
A break below EUR 40.35 would reopen the path toward the March trough, while a convincing hold — backed by reassuring pipeline commentary and solid tablet uptake — could draw buyers back into a stock that has shed roughly 40 percent of its value over the past year. Wednesday's numbers will determine which scenario unfolds, but the failed ZEUS trial has already ensured that Novo Nordisk enters the report from a position of weakness rather than strength.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
